Annovis Bio (ANVS) vs Gain Therapeutics (GANX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Gain Therapeutics (GANX) has outperformed Annovis Bio (ANVS) over the past year, losing 62.4% versus a loss of 81.2%. Over five years, GANX leads with a -87.3% price change compared with -97.2% for ANVS. Gain Therapeutics is the larger company by market cap ($44.5 million vs $44.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANVS | GANX |
|---|---|---|
| Share price | $0.7113 | $0.9994 |
| Market cap | $44.12M | $44.50M |
| 1-day change | -4.96% | -4.82% |
| YTD return | -79.44% | -68.96% |
| 1-year return | -81.23% | -62.43% |
| 5-year return | -97.24% | -87.27% |
| EPS (TTM) | $-1.55 | $-0.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Net income (latest FY) | $-28.85M | $-20.16M |
| 52-week high | $5.50 | $4.34 |
| 52-week low | $0.62 | $0.94 |
| Distance from 52-week high | -87.07% | -76.97% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +1376.17% | +620.43% |
| Average volume | 1.82M | 550.22K |
| Shares outstanding | 62.02M | 44.53M |
| Employees | 7 | 20 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GANX has outperformed ANVS by 18.8 percentage points over the past year.
About Annovis Bio
ANVS stock →Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Gain Therapeutics
GANX stock →Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees
ANVS vs GANX FAQ
Which is bigger, Annovis Bio or Gain Therapeutics?
Gain Therapeutics (GANX) is larger, with a market capitalization of $44.50M compared with $44.12M for Annovis Bio (ANVS).
Which stock has performed better over the past year, ANVS or GANX?
GANX returned -62.43% over the past 12 months, compared with -81.23% for ANVS (price return, excluding dividends). Past performance does not predict future results.
Are Annovis Bio and Gain Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.